ReviewFrontiers in immunology2026
Beyond desensitization: the SCFA-Treg-gut microbiota axis as a mechanistic framework for sustained unresponsiveness in food allergy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Food allergy is an immune-mediated condition associated with acute reactions, risk of anaphylaxis, and a substantial day-to-day management burden. Oral immunotherapy (OIT) can increase the amount of allergen tolerated during treatment, but this desensitized state commonly depends on continued exposure. Sustained unresponsiveness (SU), also termed remission in some trials, is a stricter operational endpoint in which clinical non-reactivity is retained after a predefined period of treatment withdrawal and is confirmed by oral food challenge. The biological processes that determine whether desensitization develops into SU remain incompletely understood. This narrative review evaluates the gut microbiota-short-chain fatty acid (SCFA)-regulatory T-cell (Treg) axis as a mechanistic framework for this transition. Experimental studies show that microbial SCFAs can influence Treg differentiation and function through histone deacetylase inhibition and metabolite-sensing receptors, while also conditioning epithelial and antigen-presenting-cell programs that favor mucosal tolerance. Human cohort and microbiota-transfer studies support an association between early-life microbial maturation, SCFA-related metabolic capacity, and allergic outcomes, but most causal evidence remains preclinical. Importantly, fecal SCFA concentrations are imperfect surrogates for mucosal exposure, and a randomized trial of oral butyrate added to peanut OIT did not improve SU. These findings argue against treating a single metabolite as a sufficient therapeutic target. Translational development should instead test spatially targeted metabolite delivery, defined microbial therapeutics, and precision prebiotic or synbiotic strategies as adjuncts to antigen-directed therapy. Future trials require harmonized post-withdrawal challenge definitions, longitudinal sampling of microbial function and host immunity, and biomarker-guided patient stratification. The SCFA-Treg-gut microbiota axis is therefore best viewed as a testable, integrative model of durable immune control rather than an established therapeutic pathway to SU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.